Table 1

Main characteristics of lung transplant recipients at study entry (n=112)

Female/malen 58/54,
median (range)
Age at lung transplantation (years)49.5 (11–66)
Age at study entry (years)53.5 (16–70)
n (%)
Diagnosis leading to lung transplantation
 Chronic obstructive pulmonary disease48 (42.0)
 Cystic fibrosis31 (27.7)
 Idiopathic pulmonary fibrosis6 (5.4)
 Pulmonary hypertension9 (8.0)
 Other18 (16.1)
Time since lung transplantation
 <3 months31 (27.7)
 3 months to 1 year10 (8.9)
 1–3 years18 (16.1)
 3–5 years15 (13.4)
 5–10 years27 (24.1)
 >10 years11 (9.8)
Immunosuppressive therapy
 Calcineurin inhibitors107 (96)
 Mycophenolate mofetil or azathioprine112 (100)
 mTOR inhibitors5 (4)
 Systemic corticosteroids110 (98)
Bronchiolitis obliterans syndrome (BOS) stage
 BOS 071 (63.4)
 BOS 0p20 (17.9)
 BOS 19 (8.0)
 BOS 23 (2.7)
 BOS 36 (5.4)
 BOS undetermined3 (2.7)
  • mTOR, mammalian target of rapamycin.